Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.48 |
| ▸ | SYK | P43405 | 3/20 | 0.48 |
| ▸ | SRC | P12931 | 6/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RGS12 | O14924 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | YES1 | P07947 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840677 | 1.00 | PDPK1 (0.50) | PDPK1SIRT1NTRK1SYKSRC | |
| Dimethylamine SCHEMBL7991352 | 0.96 | PDPK1 (0.49) | PDPK1SIRT1NTRK1SYKSRC | |
| SCHEMBL6394717 | 0.89 | PDPK1 (0.65) | PDPK1SIRT1NTRK1SYKSRC | |
| SCHEMBL6394720 | 0.89 | PDPK1 (0.65) | PDPK1SIRT1NTRK1SYKSRC | |
| SCHEMBL5179933 | 0.86 | SRC (0.63) | PDPK1SIRT1NTRK1SYKSRC | |
| SCHEMBL5179937 | 0.86 | SRC (0.63) | PDPK1SIRT1NTRK1SYKSRC | |
| SCHEMBL5182990 | 0.86 | SRC (0.63) | PDPK1SIRT1NTRK1SYKSRC | |
| SCHEMBL5182993 | 0.86 | SRC (0.63) | PDPK1SIRT1NTRK1SYKSRC | |
| SCHEMBL5842604 | 0.85 | CASP3 (0.58) | PDPK1SIRT1NTRK1SYKSRC | |
| SCHEMBL5842606 | 0.85 | CASP3 (0.58) | PDPK1SIRT1NTRK1SYKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | PDPK1 3/4885SIRT1 1937/4885NTRK1 1206/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | PDPK1 3/4885SIRT1 1937/4885NTRK1 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.